Search

Individuals with elevated C-reactive protein at 1.0 mg/dL and poverty had a greater risk for 15-year all-cause mortality There is a potential synergistic effect for inflammation and living in poverty with increased mortality risk for adults, according to a study published online Jan. 16 in Frontiers in Medicine. Arch G. Mainous III, Ph.D., from the University...

Multiple Myeloma Status Quo Over 30,000 Americans are diagnosed with multiple myeloma each year. And more than 12,500 Americans pass away due to multiple myeloma annually. Multiple myeloma is a cancer of plasma cells. With multiple myeloma, the bone marrow consists of excess plasma cells associated with monoclonal protein in the blood and/or urine. Clinical...

The resistance and progression of tumors in patients with classic Hodgkin lymphoma is believed at least in part to depend on features of the tumor microenvironment. However, the relationship between malignant Hodgkin/Reed-Sternberg cells, reactive populations, and immune cells is still unclear. This retrospective study, published in Cancers, sought to identify potential predictive and prognostic morphological markers in...

Immune checkpoint inhibitors (ICIs) block checkpoint proteins from binding with partner proteins, allowing T cells to kill cancer cells. They are safe and effective in treating multiple cancer types, including relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL).  This study, published in the Journal of Clinical Oncology for the 2022 ASCO Annual Meeting, sought to gather long-term...

In this MD Newsline exclusive interview with dermatologist Dr. Edidiong Kaminska, we discuss why melanoma is an important health issue. We also discuss why patients of all skin types need a skin check and sunscreen. MD Newsline: Can you explain why melanoma is an important health issue? Dr. Edidiong Kaminska: “Melanoma is a skin cancer...

Bimekizumab demonstrates overall greater efficacy than guselkumab in psoriatic arthritis patients at 52 weeks, according to an analysis of data from several trials. Approximately 30% of psoriasis patients develop psoriatic arthritis (PsA). Recent Phase 3 trials have demonstrated the efficacy and safety of bimekizumab (an interleukin-17F and IL-17A inhibitor) and guselkumab (an interleukin-23 inhibitor) in...

Various factors influencing the health-related quality of life of non-Hodgkin lymphoma survivors were revealed in a recent study. The study results highlight the links between socio-demographics, clinical attributes, and psychological conditions. This research provides a comprehensive perspective, potentially influencing tailored interventions in the future. Non-Hodgkin lymphoma survivors show distinct health-related quality of life (HRQoL) challenges....